Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384469487> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4384469487 endingPage "s219" @default.
- W4384469487 startingPage "s219" @default.
- W4384469487 abstract "Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US and other countries for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In the POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751) trials, deucravacitinib was superior to placebo and apremilast in patients with moderate to severe plaque psoriasis. This analysis evaluated deucravacitinib efficacy by baseline characteristics.
 Methods: Efficacy endpoints, including ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician’s Global Assessment score of 0 (clear) or 1 (almost clear) (sPGA 0/1), were evaluated at Week 24 by baseline subgroups including weight, sex, and PASI in the pooled PSO-1 and PSO-2 population, and at Week 52 in PSO-1 patients who received continuous deucravacitinib treatment from Day 1.
 Results: In the pooled PSO-1 and PSO-2 population, deucravacitinib (n=843) was more efficacious than apremilast (n=422) at Week 24 across subgroups defined by baseline weight (<90 kg: PASI 75, 69.8% vs 43.8%, sPGA 0/1, 60.2% vs 34.2%; ≥90 kg: PASI 75, 55.4% vs 31.5%, sPGA 0/1, 45.9% vs 25.6%), sex (male: PASI 75, 59.3% vs 33.7%, sPGA 0/1, 49.6% vs 24.7%; female: PASI 75, 70.4% vs 45.2%, sPGA 0/1, 60.9% vs 39.4%), and PASI (≤20: PASI 75, 61.6% vs 38.6%, sPGA 0/1, 53.5% vs 32.4%; >20: PASI 75, 64.7% vs 37.0%, sPGA 0/1: 53.2% vs 27.1%). Consistent efficacy was observed through Week 52 in patients who received continuous deucravacitinib treatment in PSO-1 (n=332), regardless of baseline characteristics.
 Conclusion: Deucravacitinib demonstrated consistent efficacy for up to 52 weeks regardless of baseline characteristics in patients with moderate to severe plaque psoriasis.
 
 Acknowledgments
 
 This study was sponsored by Bristol Myers Squibb
 Writing and editorial assistance was provided by Liz Rockstein, PhD, of Peloton Advantage, LLC, an OPEN Health company, funded by Bristol Myers Squibb
" @default.
- W4384469487 created "2023-07-17" @default.
- W4384469487 creator A5003926007 @default.
- W4384469487 creator A5004760940 @default.
- W4384469487 creator A5006526834 @default.
- W4384469487 creator A5007088371 @default.
- W4384469487 creator A5016544158 @default.
- W4384469487 creator A5019091788 @default.
- W4384469487 creator A5025496738 @default.
- W4384469487 creator A5033903141 @default.
- W4384469487 creator A5047076464 @default.
- W4384469487 creator A5080237247 @default.
- W4384469487 date "2023-07-17" @default.
- W4384469487 modified "2023-09-26" @default.
- W4384469487 title "Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials" @default.
- W4384469487 doi "https://doi.org/10.25251/skin.7.supp.219" @default.
- W4384469487 hasPublicationYear "2023" @default.
- W4384469487 type Work @default.
- W4384469487 citedByCount "0" @default.
- W4384469487 crossrefType "journal-article" @default.
- W4384469487 hasAuthorship W4384469487A5003926007 @default.
- W4384469487 hasAuthorship W4384469487A5004760940 @default.
- W4384469487 hasAuthorship W4384469487A5006526834 @default.
- W4384469487 hasAuthorship W4384469487A5007088371 @default.
- W4384469487 hasAuthorship W4384469487A5016544158 @default.
- W4384469487 hasAuthorship W4384469487A5019091788 @default.
- W4384469487 hasAuthorship W4384469487A5025496738 @default.
- W4384469487 hasAuthorship W4384469487A5033903141 @default.
- W4384469487 hasAuthorship W4384469487A5047076464 @default.
- W4384469487 hasAuthorship W4384469487A5080237247 @default.
- W4384469487 hasBestOaLocation W43844694871 @default.
- W4384469487 hasConcept C126322002 @default.
- W4384469487 hasConcept C142724271 @default.
- W4384469487 hasConcept C16005928 @default.
- W4384469487 hasConcept C204787440 @default.
- W4384469487 hasConcept C27081682 @default.
- W4384469487 hasConcept C2777011040 @default.
- W4384469487 hasConcept C2780564577 @default.
- W4384469487 hasConcept C2908647359 @default.
- W4384469487 hasConcept C3020604521 @default.
- W4384469487 hasConcept C71924100 @default.
- W4384469487 hasConcept C90924648 @default.
- W4384469487 hasConcept C99454951 @default.
- W4384469487 hasConceptScore W4384469487C126322002 @default.
- W4384469487 hasConceptScore W4384469487C142724271 @default.
- W4384469487 hasConceptScore W4384469487C16005928 @default.
- W4384469487 hasConceptScore W4384469487C204787440 @default.
- W4384469487 hasConceptScore W4384469487C27081682 @default.
- W4384469487 hasConceptScore W4384469487C2777011040 @default.
- W4384469487 hasConceptScore W4384469487C2780564577 @default.
- W4384469487 hasConceptScore W4384469487C2908647359 @default.
- W4384469487 hasConceptScore W4384469487C3020604521 @default.
- W4384469487 hasConceptScore W4384469487C71924100 @default.
- W4384469487 hasConceptScore W4384469487C90924648 @default.
- W4384469487 hasConceptScore W4384469487C99454951 @default.
- W4384469487 hasIssue "4" @default.
- W4384469487 hasLocation W43844694871 @default.
- W4384469487 hasOpenAccess W4384469487 @default.
- W4384469487 hasPrimaryLocation W43844694871 @default.
- W4384469487 hasRelatedWork W2028656318 @default.
- W4384469487 hasRelatedWork W2077277924 @default.
- W4384469487 hasRelatedWork W2124441198 @default.
- W4384469487 hasRelatedWork W2126375175 @default.
- W4384469487 hasRelatedWork W2520935772 @default.
- W4384469487 hasRelatedWork W2604898777 @default.
- W4384469487 hasRelatedWork W3084176453 @default.
- W4384469487 hasRelatedWork W3110108782 @default.
- W4384469487 hasRelatedWork W4206835797 @default.
- W4384469487 hasRelatedWork W4226392780 @default.
- W4384469487 hasVolume "7" @default.
- W4384469487 isParatext "false" @default.
- W4384469487 isRetracted "false" @default.
- W4384469487 workType "article" @default.